Home / Market News / $BMY
benzinga Corporate Catalyst Impact 55/100 ● negative

Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

Oct 8, 2026, 10:41 AM UTC · Primary ticker $BMY

Cantor Fitzgerald analyst Carter Gould has reiterated a Neutral rating on Bristol-Myers Squibb (BMY) but reduced its price target from $59 to $53. This adjustment reflects a revised valuation perspective from the analyst, which could influence investor sentiment and short-term trading around BMY.

Cantor Fitzgerald analyst Carter Gould has maintained a 'Neutral' rating on Bristol-Myers Squibb (BMY) but significantly lowered the price target from $59 to $53. This action indicates a revised outlook on the company's valuation by a prominent analyst, suggesting potential headwinds or a more conservative growth projection. While the 'Neutral' rating implies no immediate strong buy or sell recommendation, the reduced price target could exert downward pressure on BMY's stock in the short term as investors react to the updated valuation. For traders, this presents a short-term risk of price depreciation, though the long-term implications depend on BMY's fundamental performance and future pipeline developments. The key risk is that other analysts may follow suit, further dampening investor confidence.

$BMY negative Price target lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.